Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTADEG1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	DEC 01	ChemPort single article sales feature unavailable
NEWS 3	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 4	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS 5	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 6	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 7	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS 8	FEB 10	COMPENDEX reloaded and enhanced
NEWS 9	FEB 11	WTEXTILES reloaded and enhanced
NEWS 10	FEB 19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art
NEWS 11	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS 12	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS 13	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS 14	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS 15	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS 16	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS 17	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS 18	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS 19	MAR 11	ESBIOBASE reloaded and enhanced
NEWS 20	MAR 20	CAS databases on STN enhanced with new super role for nanomaterial substances
NEWS 21	MAR 23	CA/CAplus enhanced with more than 250,000 patent equivalents from China
NEWS 22	MAR 30	IMSPATENTS reloaded and enhanced
NEWS 23	APR 03	CAS coverage of exemplified prophetic substances enhanced
NEWS 24	APR 07	STN is raising the limits on saved answers

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

```
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 08:06:40 ON 14 APR 2009

=> file registry
COST IN U.S. DOLLARS                                 SINCE FILE      TOTAL
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                       0.22       0.22

FILE 'REGISTRY' ENTERED AT 08:06:59 ON 14 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   13 APR 2009  HIGHEST RN 1134263-89-0
DICTIONARY FILE UPDATES:  13 APR 2009  HIGHEST RN 1134263-89-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10-597836genA.str
```





chain nodes :
13 14 15 16 17 18 20
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
5-16 6-13 7-18 10-13 13-15 13-14 16-17 17-20
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
13-15 13-14 17-20
exact bonds :
5-16 6-13 7-18 10-13 16-17
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

G1:C,H

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
20:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,H

Structure attributes must be viewed using STN Express query preparation.

=>
Uploading C:\Program Files\Stnexp\Queries\10-597836genB.str





chain nodes :
13 14 15 16 17 18 20 22
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
5-16 6-13 7-18 10-13 13-15 13-14 14-22 16-17 17-20
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
13-15 14-22 17-20
exact bonds :
5-16 6-13 7-18 10-13 13-14 16-17
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

G1:C,H

G2:C,H,O,N,CN

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
20:CLASS 22:CLASS

L2 STRUCTURE UPLOADED

=> d l2
L2 HAS NO ANSWERS
L2 STR



G1 C,H
G2 C,H,O,N,CN

Structure attributes must be viewed using STN Express query preparation.

=> s l2 sss full
FULL SEARCH INITIATED 08:16:20 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 539 TO ITERATE

100.0% PROCESSED 539 ITERATIONS 127 ANSWERS
SEARCH TIME: 00.00.01

L3 127 SEA SSS FUL L2

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 193.08 193.30

FILE 'CAPLUS' ENTERED AT 08:16:33 ON 14 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 14 Apr 2009 VOL 150 ISS 16
FILE LAST UPDATED: 13 Apr 2009 (20090413/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

```
=> s l3
L4          68 L3

=> s l4 and pd<20040300
      24836013 PD<20040300
                (PD<20040300)
L5          24 L4 AND PD<20040300

=> s l5 and (anhydride or imide or precipitate)
         241598 ANHYDRIDE
          35581 ANHYDRIDES
         253168 ANHYDRIDE
                (ANHYDRIDE OR ANHYDRIDES)
          25820 IMIDE
          11104 IMIDES
          31613 IMIDE
                (IMIDE OR IMIDES)
          16155 PRECIPITATE
          15240 PRECIPITATES
          29451 PRECIPITATE
                (PRECIPITATE OR PRECIPITATES)
         208189 PPT
          71553 PPTS
         259282 PPT
                (PPT OR PPTS)
         277250 PRECIPITATE
                (PRECIPITATE OR PPT)
L6           4 L5 AND (ANHYDRIDE OR IMIDE OR PRECIPITATE)

=> d l6 1-4 abs ibib hitstr

L6   ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2009 ACS on STN
AB   The enzymic resolution of 4-[4-(Dimethylamino)-1-(4-fluorophenyl)-1-
     hydroxybutyl]-3-(hydroxymethyl)benzonitrile, a useful intermediate in the
     synthesis of enantiomerically pure citalopram, has been studied.  Candida
     antarctica lipase B (CAL-B) catalyzes the enzymic acetylation of the
     primary benzylic alc. with high enantioselectivity at the quaternary
     stereogenic center.  This enzymic acetylation yielded the acetylated
```

(+)-3-[(acetyloxy)methyl]-4-[(1R)-4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]benzonitrile and the desired (-)-4-[(1S)-4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)benzonitrile. The enzymic enantioselective hydrolysis of the 3-acetyloxymethyl derivative catalyzed by CAL-B is also possible.

ACCESSION NUMBER: 2004:40088 CAPLUS
DOCUMENT NUMBER: 140:287145
TITLE: Enzymatic resolution of a quaternary stereogenic center as the key step in the synthesis of (S)-(+)-citalopram
AUTHOR(S): Solares, Laura F.; Brieva, Rosario; Quiros, Margarita; Llorente, Isidro; Bayod, Miguel; Gotor, Vicente
CORPORATE SOURCE: Departamento de Quimica Organica e Inorganica, Facultad de Quimica, Universidad de Oviedo, Oviedo, 33071, Spain
SOURCE: Tetrahedron: Asymmetry (2004), 15(2), 341-345
CODEN: TASYE3; ISSN: 0957-4166
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 140:287145

IT 481047-48-7P
RL: BPN (Biosynthetic preparation); BIOL (Biological study); PREP (Preparation)
(regioselective, chemoselective enzymic acetylation and resolution of [(dimethylamino)(fluorophenyl)(hydroxy)butyl](hydroxymethyl)benzonitrile as key step in synthesis of (S)-(+)-citalopram)

RN 481047-48-7 CAPLUS
CN Benzonitrile, 4-[(1R)-4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 488787-59-3P
RL: BPN (Biosynthetic preparation); RCT (Reactant); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(regioselective, chemoselective enzymic acetylation and resolution of [(dimethylamino)(fluorophenyl)(hydroxy)butyl](hydroxymethyl)benzonitrile as key step in synthesis of (S)-(+)-citalopram)

RN 488787-59-3 CAPLUS
CN Benzonitrile, 4-[(1S)-4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 674806-13-4P 674806-14-5P
RL: BPN (Biosynthetic preparation); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(regioselective, chemoselective enzymic acetylation and resolution of [(dimethylamino)(fluorophenyl)(hydroxy)butyl](hydroxymethyl)benzonitril e as key step in synthesis of (S)-(+)-citalopram)
RN 674806-13-4 CAPLUS
CN Benzonitrile, 3-[(acetyloxy)methyl]-4-[(1R)-4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 674806-14-5 CAPLUS
CN Benzonitrile, 3-[(acetyloxy)methyl]-4-[(1S)-4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 103146-25-4, 4-[4-(Dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)benzonitrile
RL: RCT (Reactant); RACT (Reactant or reagent)
(regioselective, chemoselective enzymic acetylation and resolution of [(dimethylamino)(fluorophenyl)(hydroxy)butyl](hydroxymethyl)benzonitril e as key step in synthesis of (S)-(+)-citalopram)
RN 103146-25-4 CAPLUS
CN Benzonitrile, 4-[4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)- (CA INDEX NAME)



IT 674806-15-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(regioselective, chemoselective enzymic acetylation and resolution of [(dimethylamino)(fluorophenyl)(hydroxy)butyl](hydroxymethyl)benzonitrile as key step in synthesis of (S)-(+)-citalopram)
RN 674806-15-6 CAPLUS
CN Benzonitrile, 3-[(acetyloxy)methyl]-4-[4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]- (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
GI



I



II

AB Preparation of escitalopram (I) via the chiral enriched monoacetate ester of (4-bromo-2-(hydroxymethyl)phenyl)-(4-fluorophenyl)methanol (II) was disclosed. For example, a racemic mixture of monoacetate ester II (13.52 g)

and (+)-di-p-toluoyl tartaric acid (11.92 g) in acetone (135 mL) was heated at reflux until a pale brown solution was obtained. The solution was cooled, the acetone removed under vacuum and the resulting brown foam recrystd. from acetone-hexane (2:1) to afford the (+)-di-p-toluoyl tartaric acid salt of monoacetate ester II with a diastereomeric ratio of 97:3. Of note, the claimed (+)-di-p-toluoyl tartaric acid salt of monoacetate ester II was converted to escitalopram oxalate in 4-steps with [α]D = +10.1° (at 20°C, c 0.95 in MeOH).

ACCESSION NUMBER: 2003:837069 CAPLUS
DOCUMENT NUMBER: 139:337880
TITLE: Preparation of escitalopram via the chiral enriched diol monoesters of (4-bromo-2-(hydroxymethyl)phenyl)-(4-fluorophenyl)methanol
INVENTOR(S): Tse, Hoi Lun Allan
PATENT ASSIGNEE(S): Torcan Chemical Ltd., Can.
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003087081	A1	20031023	WO 2003-CA522	20030408 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2381341	A1	20031009	CA 2002-2381341	20020409 <--
AU 2003218575	A1	20031027	AU 2003-218575	20030408 <--
EP 1495013	A1	20050112	EP 2003-711761	20030408
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20060009515	A1	20060112	US 2005-510890	20050311
PRIORITY APPLN. INFO.:			CA 2002-2381341 A	20020409
			WO 2003-CA522 W	20030408

OTHER SOURCE(S): CASREACT 139:337880
IT 488148-10-3P 488148-12-5P 616217-14-2P 616217-15-3P 616217-16-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of escitalopram via a chiral enriched diol monoester intermediate)
RN 488148-10-3 CAPLUS
CN 1,2-Benzenedimethanol, 4-bromo-α1-[3-(dimethylamino)propyl]-α1-(4-fluorophenyl)- (CA INDEX NAME)



RN 488148-12-5 CAPLUS
CN 1,2-Benzenedimethanol, 4-bromo-α1-[3-(dimethylamino)propyl]-α1-(4-fluorophenyl)-, (α1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 616217-14-2 CAPLUS
CN 1,2-Benzenedimethanol, 4-bromo-α1-[3-(dimethylamino)propyl]-α1-(4-fluorophenyl)-, 2-acetate (CA INDEX NAME)



RN 616217-15-3 CAPLUS
CN 1,2-Benzenedimethanol, 4-bromo-α1-[3-(dimethylamino)propyl]-α1-(4-fluorophenyl)-, 2-acetate, (α1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 616217-16-4 CAPLUS
CN Butanedioic acid, 2,3-bis[(4-methylbenzoyl)oxy]-, (2S,3S)-, compd. with [5-bromo-2-[(1S)-4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]phenyl]methyl acetate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 616217-15-3
CMF C21 H25 Br F N O3

Absolute stereochemistry.



CM 2

CRN 32634-68-7
CMF C20 H18 O8

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 4 CAPLUS
GI



I



II



III

AB This invention relates to the preparation of I and II and derivs. of I and II in their racemic, enantiomerically enriched, or optically pure forms. This invention further relates to novel compns. of matter containing enantiomerically enriched (-)-desmethylcitalopram (-)-III (R = Me), (+)-didesmethylcitalopram (+)-III (R = Me), or (-)-didesmethylcitalopram (-)-III (R = H) or mixts. thereof in optimal ratios. Contrary to prior teachings, the enantiomerically enriched citalopram metabolites disclosed herein possess potent serotonin reuptake inhibitory activity, with minimal inhibitory effects on the reuptake of other known monoamines, e.g., norepinephrine (NE) or dopamine (DA). For example, stepwise reaction of 1-oxo-1,3-dihydroisobenzofuran-5-carbonitrile with 4-fluorophenylmagnesium bromide and the chiral Grignard reagent, which was prepared from 2-(2-bromoethyl)-[1,3]dioxolane and Mg powder, in THF gave II. Cyclization using mesyl chloride in CH2C12, followed by reduction provided the I. Reaction of the aldehyde with (-)-tert-butylsulfinamide in the presence of Ti(OEt)4 in EtOH afforded the sulfinamide, which was reduced to the amine III (R = H) with 10% HCl in MeOH. Protection of the amine with BOC anhydride in the presence of TEA in CH2C12 provided the enantiomerically enriched isomers, which were separated on a chiral column and subsequently deprotected with TFA to give (+)-III (R = H) and (-)-III (R = H). In biol. assays, (-)-III (R = H) and (+)-III (R = H) strongly inhibited serotonergic 5-HT receptor activity with Ki values of 5.8 nM and 90 nM, resp., with little effect on NE and DA transporter activity. By comparison, racemic citalopram inhibited serotonin reuptake with a Ki of 3.9 nM. The present invention also discloses methods for treating disorders, dysfunctions and diseases for which inhibition of serotonin reuptake is therapeutically beneficial. In particular, the present invention discloses a method for treating various forms of depression and other CNS disorders with pharmaceutical compns. described herein.

ACCESSION NUMBER: 2003:376842 CAPLUS
DOCUMENT NUMBER: 138:385297
TITLE: Methods for treating depression and other CNS disorders using enantiomerically enriched desmethyl- and didesmethyl- metabolites of citalopram

INVENTOR(S): Bush, Larry R.; Currie, Mark G.; Senanayake, Chris H.; Fang, Kevin Q.
PATENT ASSIGNEE(S): Sepracor, Inc., USA
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003040121	A1	20030515	WO 2002-US35408	20021105 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2465186	A1	20030515	CA 2002-2465186	20021105 <--
AU 2002356903	A1	20030519	AU 2002-356903	20021105 <--
AU 2002356903	A2	20030519		
EP 1446396	A1	20040818	EP 2002-802848	20021105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002013949	A	20040831	BR 2002-13949	20021105
HU 2004001934	A2	20050128	HU 2004-1934	20021105
HU 2004001934	A3	20070529		
JP 2005510518	T	20050421	JP 2003-542167	20021105
CN 1705654	A	20051207	CN 2002-822084	20021105
NZ 532478	A	20070223	NZ 2002-532478	20021105
IN 2004KN00505	A	20060616	IN 2004-KN505	20040419
ZA 2004003409	A	20051026	ZA 2004-3409	20040505
MX 2004004368	A	20040811	MX 2004-4368	20040507
US 20040266864	A1	20041230	US 2004-842055	20040507
NO 2004002013	A	20040514	NO 2004-2013	20040514

PRIORITY APPLN. INFO.: US 2001-337608P P 20011108
WO 2002-US35408 W 20021105

IT 526204-34-2P, 4-[3-([1,3]Dioxolan-2-yl)-1-(4-fluorophenyl)-1-hydroxypropyl]-3-hydroxymethylbenzonitrile 526204-42-2P, (R)-4-[3-([1,3]Dioxolan-2-yl)-1-(4-fluorophenyl)-1-hydroxypropyl]-3-hydroxymethylbenzonitrile
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of enantiomerically enriched desmethyl- and didesmethyl- metabolites of citalopram for treating depression and other CNS disorders)
RN 526204-34-2 CAPLUS
CN Benzonitrile, 4-[3-(1,3-dioxolan-2-yl)-1-(4-fluorophenyl)-1-hydroxypropyl]-3-(hydroxymethyl)- (CA INDEX NAME)



RN 526204-42-2 CAPLUS
CN Benzonitrile, 4-[(1R)-3-(1,3-dioxolan-2-yl)-1-(4-fluorophenyl)-1-hydroxypropyl]-3-(hydroxymethyl)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
GI



AB There is described a process for the preparation of citalopram (shown as I) and of its pharmaceutically acceptable salts, which comprises treating a 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbaldoxime, O-substituted preferably with a diphenylmethyl or triphenylmethyl group, with formic-acetic anhydride. Furthermore, the total synthesis of citalopram, as free base or as its pharmaceutically acceptable salt, starting from 5-formylphthalide is described.
ACCESSION NUMBER: 2003:96293 CAPLUS

DOCUMENT NUMBER: 138:137156
TITLE: Process for the preparation of 5-substituted isobenzofurans including citalopram
INVENTOR(S): Dall'asta, Leone; Cotticelli, Giovanni
PATENT ASSIGNEE(S): Infosint SA, Switz.
SOURCE: Eur. Pat. Appl., 22 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1281707	A1	20030205	EP 2001-830517	20010802 <--
EP 1281707	B1	20041229		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AT 286037	T	20050115	AT 2001-830517	20010802
ES 2234797	T3	20050701	ES 2001-830517	20010802
CA 2456004	A1	20030213	CA 2002-2456004	20020729 <--
WO 2003011846	A2	20030213	WO 2002-EP8550	20020729 <--
WO 2003011846	A3	20031127		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002325385	A1	20030217	AU 2002-325385	20020729 <--
AU 2002325385	B2	20070705		
BR 2002011858	A	20040921	BR 2002-11858	20020729
HU 2004001166	A2	20040928	HU 2004-1166	20020729
HU 2004001166	A3	20070529		
CN 1555370	A	20041215	CN 2002-818323	20020729
CN 1298713	C	20070207		
JP 2005501056	T	20050113	JP 2003-517038	20020729
RO 122147	B1	20090130	RO 2004-84	20020729
TW 225055	B	20041211	TW 2002-91117176	20020731
BG 108554	A	20050331	BG 2004-108554	20040130
US 20040230065	A1	20041118	US 2004-776625	20040131
US 7166729	B2	20070123		
MX 2004001030	A	20041203	MX 2004-1030	20040202
ZA 2004000841	A	20050202	ZA 2004-841	20040202
IN 2004KN00132	A	20060407	IN 2004-KN132	20040204
HK 1070357	A1	20070810	HK 2005-102982	20050408

PRIORITY APPLN. INFO.: EP 2001-830517 A 20010802
WO 2002-EP8550 W 20020729

OTHER SOURCE(S): CASREACT 138:137156; MARPAT 138:137156

IT 493015-02-4P, O-Benzyl-3-hydroxymethyl-4-[α-hydroxy-α-[3-(dimethylamino)propyl]-4-fluorobenzyl]benzaldoxime 493015-07-9P, O-Triphenylmethyl-3-hydroxymethyl-4-[α-hydroxy-α-[3-(dimethylamino)propyl]-4-fluorobenzyl]benzaldoxime
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process for preparation of 5-substituted isobenzofurans including citalopram)

RN 493015-02-4 CAPLUS

CN Benzaldehyde, 4-[4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-, O-(phenylmethyl)oxime (CA INDEX NAME)



RN 493015-07-9 CAPLUS
CN Benzaldehyde, 4-[4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-, O-(triphenylmethyl)oxime (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log off
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
STN INTERNATIONAL LOGOFF AT 08:26:56 ON 14 APR 2009